KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Others

Ratios

Takeda Pharmaceutical (TAK) Liabilities from Discontinued Operations (2026)

Takeda Pharmaceutical has reported Liabilities from Discontinued Operations over the past 1 years, most recently at 5216017.89 for Q1 2026.

For Q1 2026, Liabilities from Discontinued Operations changed N/A year-over-year to 5216017.89; the TTM value through Mar 2026 reached 5216017.89, changed N/A, while the annual FY2026 figure was 5434125.06, N/A changed from the prior year.
Liabilities from Discontinued Operations was 5216017.89 for Q1 2026 at Takeda Pharmaceutical.
Across five years, Liabilities from Discontinued Operations topped out at 5216017.89 in Q1 2026 and bottomed at 5216017.89 in Q1 2026.